Key points from article :
Rejuveron strengthened its support to a near-majority holding in Endogena Therapeutics.
Provided $4.75 million as part of Endogena's $8m series A-1 financing round.
$20m in series A financing round to enable Endogena to progress treatments targeting degenerative diseases of the eye.
Endogena's novel, small-molecule approach is gene-independent, which has significant advantages in RP.
Lead photoreceptor regeneration treatment (EA-2353) for retinitis pigmentosa (RP) to progress through first-in-human trials.
EA-2353 works by selective regulation of the endogenous adult stem- and progenitor cells for controlled tissue repair.
EA-2353 will enter first-in-human trials in the first half of 2022.
To advance EA-2351, a treatment for geographic atrophy (GA) to IND.
Potential to become a paradigm shift in treating degenerative conditions related to aging and genetic disorders.
Christian Angermayer, Chairman of Rejuveron, said: "Regenerative therapies will have a more prominent role in expanding the healthspan of our aging population, which is facing the increasing burden of social, economic and healthcare challenges of age-related demographic shifts."
Matthias Steger, CEO of Endogena, said: "Our small molecule drug discovery expertise, AI-driven platform combined with our state-of-the-art stem cell know-how will enable us to advance breakthrough therapies in several indications."
